127 related articles for article (PubMed ID: 15640610)
1. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients.
Driss F; Vrtovsnik F; Katsahian S; Michel C; Baron G; Kolta A; Sedrati N; Mentré F; Mignon F; Cabantchik I; Grandchamp B
Nephron Clin Pract; 2005; 99(3):c63-7. PubMed ID: 15640610
[TBL] [Abstract][Full Text] [Related]
2. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
3. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron.
Prakash M; Upadhya S; Prabhu R
Clin Chim Acta; 2005 Oct; 360(1-2):194-8. PubMed ID: 15979061
[TBL] [Abstract][Full Text] [Related]
4. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
5. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
6. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
8. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection.
Stefánsson BV; Haraldsson B; Nilsson U
Free Radic Biol Med; 2008 Nov; 45(9):1302-7. PubMed ID: 18775775
[TBL] [Abstract][Full Text] [Related]
9. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
Scheiber-Mojdehkar B; Lutzky B; Schaufler R; Sturm B; Goldenberg H
J Am Soc Nephrol; 2004 Jun; 15(6):1648-55. PubMed ID: 15153577
[TBL] [Abstract][Full Text] [Related]
10. Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose.
Barton Pai A; Pai MP; Depczynski J; McQuade CR; Mercier RC
Am J Nephrol; 2006; 26(3):304-9. PubMed ID: 16809897
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
12. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
[TBL] [Abstract][Full Text] [Related]
14. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
16. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
17. Does non-transferrin bound iron contribute to transfusion related immune-modulation in preterms?
Stark MJ; Keir AK; Andersen CC
Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F424-9. PubMed ID: 23475935
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
19. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
20. Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients.
van Zyl-Smit R; Halkett JA
Nephron; 2002 Oct; 92(2):316-23. PubMed ID: 12218309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
